Patents Assigned to AstraZeneca
  • Pyridine compounds
    Patent number: 8569298
    Abstract: The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: October 29, 2013
    Assignee: Astrazeneca AB
    Inventors: Bernard Christophe Barlaam, Patrick Ple, Kevin Michael Foote, Clifford David Jones
  • Process for preparing [1-[1-?, 2-?, 3-?(1*,2*) 5-?]]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3-1,2,3-triazolo [4,5-] pyrimidin-3-yl]-5-(2-hydroxyethoxy) cyclopentane-1,2-diol and to its intermediates
    Patent number: 8563755
    Abstract: The present invention is directed to a process for preparing [1S-[1?,2?,3?(1S*,2R*),5?]]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol and to intermediates useful in the process.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: October 22, 2013
    Assignee: AstraZeneca AB
    Inventors: Martin Hans Bohlin, Helena Hellström, Peter W Johansson, Ulf G Larsson, Mikaela Recknagel, Rhony Aufdenblatten, Ursula Weiss
  • Treatment of hibernating myocardium with an exendin peptide
    Patent number: 8551947
    Abstract: Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: October 8, 2013
    Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LP
    Inventors: Thomas R. Coolidge, Mario Ehlers
  • Chemical compounds
    Patent number: 8552004
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: October 8, 2013
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Paul Turner, Johannes Wilhelmus Maria Nissink
  • (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds
    Patent number: 8546375
    Abstract: Disclosed herein are azetidinyl compounds of formula I, as described herein, pharmaceutical compositions comprising an azetidinyl compound, and a method of using an azetidinyl compound in the treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: October 1, 2013
    Assignee: AstraZeneca AB
    Inventors: Susanne Doris Margit Bökman-Winiwarter, Marlene Fredenwall, Carl Anders Hogner, Lars Anders Mikael Johansson, Robert Andrew Judkins, Lanna Li, Björn Christian Ingvar Löfberg, Sverker Von Unge
  • Bilayer tablet formulations
    Patent number: 8535715
    Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: September 17, 2013
    Assignees: Bristol-Myers Squibb Company, AstraZeneca UK Limited
    Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
  • Melanocortin Receptor-Specific Peptides
    Publication number: 20130237473
    Abstract: The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and/or energy balance and body weight related diseases, disorders and/or conditions, including obesity, overweight and diseases, disorders and/or conditions associated with obesity and/or overweight, such as type 2 diabetes and metabolic syndrome.
    Type: Application
    Filed: May 3, 2013
    Publication date: September 12, 2013
    Applicant: AstraZeneca AB
    Inventors: John H. Dodd, Yi-Qun Shi, Wei Yang
  • Injectable Emulsion of Sedative Hypnotic Agent
    Publication number: 20130236501
    Abstract: The present invention provides novel pharmaceutical formulations of a substituted phenylacetic acid ester compound, which is useful as a short-acting sedative hypnotic agent for anesthesia and sedation. The pharmaceutical formulations are oil-in-water emulsions suitable for administration by injection. The invention further provides processes for the preparation of the formulation and the use of the formulation in medical treatment of a mammal.
    Type: Application
    Filed: May 12, 2011
    Publication date: September 12, 2013
    Applicant: ASTRAZENECA AB
    Inventors: Jonathan Booth, Leigh Dixon, Clive Washington
  • INJECTABLE EMULSION OF SEDATIVE HYPNOTIC AGENT
    Publication number: 20130237548
    Abstract: Polymorphs of 7-methyl-5-(3-piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one mesylate salt, methods of making these polymorphs and uses thereof.
    Type: Application
    Filed: April 21, 2011
    Publication date: September 12, 2013
    Applicant: ASTRAZENECA AB
    Inventors: Helen Blade, Stephen David Cosgrove
  • Chromenone derivatives
    Patent number: 8530470
    Abstract: The invention concerns chromenone compounds of Formula I; or pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, n and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: September 10, 2013
    Assignee: Astrazeneca AB
    Inventors: Bernard Christophe Barlaam, Sebastien Louis Degorce, Christine Marie Paul Lambert-Van Der Brempt, Jean-Jacques Marcel Lohmann, Patrick Ple
  • Inhaler device that reduces the risk for miscounting a dosage
    Patent number: 8528545
    Abstract: Inhaler device (10) comprising an actuator body (20) and an inhaler canister assembly (70), the inhaler canister assembly (70) is comprised of a canister (30) with a metering valve at a valve end and a dose counter unit (60) attached to a base end thereof. Further, the inhaler canister assembly (70) comprises first position ensuring means (110, 230), the actuator body comprises second position ensuring means (120,210), wherein the first and second position ensuring means being complementary mating means, and the first and second position ensuring means being so arranged that the inhaler device (10) cannot be fired, nor the counter unit (60) count unless the first and second position ensuring means are in a mating relationship. There is also provided an inhaler canister assembly (70) and an actuator body (20).
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: September 10, 2013
    Assignee: AstraZeneca AB
    Inventors: Darren Hodson, William Treneman
  • Phenoxyacetic acid derivatives useful for treating respiratory diseases
    Patent number: 8524715
    Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: September 3, 2013
    Assignee: Astrazeneca AB
    Inventors: Roger Victor Bonnert, Lilian Alcaraz, Rukhsana Tasneem Mohammed, Anthony Ronald Cook, Stephen Thom, Timothy Jon Luker
  • Imidazoquinolines with Immuno-Modulating Properties
    Publication number: 20130225555
    Abstract: The present invention provides compounds of formula (I) wherein Ra, R1, R2, R3, X1, Y1, Z1, A, n and m are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 29, 2013
    Applicants: Dainippon Sumitomo Pharma Co., Ltd., AstraZeneca AB
    Inventors: AstraZeneca AB, Dainippon Sumitomo Pharma Co., Ltd.
  • New Process for the Preparation of Aryl Substituted Olefinic Amines
    Publication number: 20130225827
    Abstract: An improved process for the preparation of aryl substituted olefinic amines such as (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine and (2S)-(4E)-N-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine and new intermediates used in said process.
    Type: Application
    Filed: May 19, 2011
    Publication date: August 29, 2013
    Applicants: TARGACEPT, INC., ASTRAZENECA AB
    Inventors: Gary Maurice Dull, John Genus, Tommi Ratilainen, Per Olof Ryberg, Janna Hellstrom, Niklas Wahlstrom, Thomas Wannman
  • Inhaler Comprising A Base Having A Plurality of Medicament Containing Sealed Cavities
    Publication number: 20130220320
    Abstract: An inhaler which comprises a base having a plurality of consecutive sealed cavities containing medicament. Foil portions are on one side attached to the base for sealing the medicament within respective associated cavities. A plurality of separating elements are attached to the other side of the foil portions, each separating element being associated with a respective cavity for separating a foil portion from that cavity. Each separating element can be moved-away from its associated cavity so that the sealing foil portion is separated from the cavity which is thereby uncovered so that medicament contained therein is enabled to become entrained in a fluid flow, and then returned with the attached foil portion to cover its associated cavity. A method of operating an inhaler is also disclosed.
    Type: Application
    Filed: February 7, 2013
    Publication date: August 29, 2013
    Applicant: AstraZeneca AB
    Inventor: AstraZeneca AB
  • Crystalline Form of Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] Calcium Salt
    Publication number: 20130225622
    Abstract: Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.
    Type: Application
    Filed: April 8, 2013
    Publication date: August 29, 2013
    Applicant: AstraZeneca UK Limited
    Inventor: AstraZeneca UK Limited
  • Prevention And Treatment Of Cardiac Arrhythmias
    Publication number: 20130209586
    Abstract: Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.
    Type: Application
    Filed: March 4, 2013
    Publication date: August 15, 2013
    Applicants: ASTRAZENECA LP, AMYLIN PHARMACEUTICALS, LLC
    Inventors: AMYLIN PHARMACEUTICALS, LLC, ASTRAZENECA LP
  • Compounds and Their Use as BACE Inhibitors
    Publication number: 20130210837
    Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 15, 2013
    Applicant: ASTRAZENECA INTELLECTUAL PROPERTY
    Inventors: Gabor Csjernyik, Sofia Karlstrom, Annika Kers, Karin Kolmodin, Martin Nylof, Liselotte Ohberg, Laszlo Rakos, Lars Sandberg, Fernando Sehgelmeble, Peter Soderman, Britt-Marie Swahn, Stefan Von Berg
  • Bi-aryl amide compounds as CRTh2 receptor modulators
    Patent number: 8507544
    Abstract: The present invention relates to (2S)-2-({3?-Chloro-4?-[(2,2-dimethylpyrrolidin-1-yl) carbonyl]-5-fluorobiphenyl-2-yl}oxy)propanoic acid and (2R)-2-({3?-chloro-4?-[(2,2-dimethylpyrrolidin-1-yl) carbonyl]-5-fluorobiphenyl-2-yl}oxy)propanoic acid of formula (I), and crystalline forms and pharmaceutically acceptable salts thereof useful as pharmaceuticals.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: August 13, 2013
    Assignee: Astrazeneca AB
    Inventors: Roger Victor Bonnert, Timothy Jon Luker, Anil Patel, Aaron Rigby
  • BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS
    Publication number: 20130203730
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.
    Type: Application
    Filed: March 13, 2013
    Publication date: August 8, 2013
    Applicant: AstraZeneca AB
    Inventor: AstraZeneca AB